The trusted source for
healthcare information and
Novartis Pharmaceuticals in East Hanover, NJ recently received approval from the U.S. Food and Drug Administration in Rockville, MD, for Starlix (nateglinide), the first D-phenylalanine derivative. Starlix has been approved as both initial monotherapy and in combination with metformin in patients with type 2 diabetes whose blood glucose is not controlled by exercise and diet.
Starlix stimulates rapid, short-acting insulin secretion that reduces the mealtime increase in blood glucose levels or spikes, and effectively lowers overall blood sugar levels as measured by HbA1c.
In a 24-week, randomized, double-blind, placebo-controlled study of 701 patients with type 2 diabetes, researchers found that Starlix alone effectively controlled mealtime glucose spikes and reduced overall glucose levels as measured by HbA1c. In the same study, researchers found that the combination of Starlix and metformin was complementary and resulted in even greater reductions in HbA1c than either agent alone.
For further information, visit www.novartis.com or call (877) 782-7549 for prescribing information.